Ichnos Glenmark Innovation to present phase 1 study data on Trispecific Antibody ISB 2001 at ASH… EP News Bureau Nov 6, 2024 Early results show promising response rates and safety profile for ISB 2001 in relapsed/refractory multiple myeloma patients
